Part, Chapter, Paragraph
1 I, 2. 5 | particularly sustained for the male section of the population, while
2 I, 2. 7 | Rural neglect. As the section on the policy tools indicated,
3 II, 5. 1. 1| conditions and problems~See section 5.6.~Respiratory diseases
4 II, 5. 2. 5| for diabetes mellitus see Section 3.1.5. Annex 1 is also relevant
5 II, 5. 3. 6| 1999 and 2000-2002. In this Section mainly macro-analysis results
6 II, 5. 4. 4| shown in the presentation section indicates an objective difficulty
7 II, 5. 4. 6| As shown in the previous section on data presentation, the
8 II, 5. 4. 6| process indicators reported in section 5.4.3, which indicate clearly
9 II, 5. 5. 1| see also the introductory Section 5.5.1.~ ~Mood and anxiety
10 II, 5. 5. 3| Gissler M, Wahlbeck K), Section B, p. 257-333, 2007.~htt df~
11 II, 5. 5. 3| spreadsheets in the data query section. The whole database will
12 II, 5. 5. 3| Disorder Society-European Section. Part I: early (uncomplicated)
13 II, 5. 6. 3| described in the following section in terms of definitions,
14 II, 5. 6. 6| Sambrook) Mosby-Elsevier; Section C, Chapter 1.~Zollman C,
15 II, 5. 8. 2| The data presented in this section are:~- Data derived from
16 II, 5. 8. 3| description and analysis~ ~This section addresses incidence, prevalence
17 II, 5. 9. FB| The data presented in this section are:~- derived from papers
18 II, 5. 9. 2| The data presented in this section are:~- Data derived from
19 II, 5. 10. 2| Community legislation (see section 5). EuroPrevall is still
20 II, 5. 10. 3| intolerant to food (see section 5.10.3.1.) and the number
21 II, 5. 11. 3| cure.~Other eczemas in this section refer to any eczema that
22 II, 5. 11. 6| analysis of the available data section is that: i) skin disease
23 II, 6. 3. 3| transmitted infections (STI)~This section addresses Chlamydia infections
24 II, 6. 3. 3| Blood-borne viral infections~This section addresses hepatitis B and
25 II, 6. 3. 4| tract infections~ ~This section addresses influenza, tuberculosis,
26 II, 6. 3. 4| drug-resistant disease (see section on antimicrobial resistance,
27 II, 7. 4 | presented in the previous section meet the European standards (
28 II, 8. 2. 1| rate of prevalence. This section presents an overview of
29 II, 9 | References cited in the section on congenital anomalies
30 II, 9 | interactive data) (see also Section 10.2).~ ~Cannabis use. Cannabis
31 II, 9 | interactive data) (see also Section 10.2).~ ~Sexual health and
32 II, 9. 1. 1| knowledge see Table 9.1 and the section on maternal health.~ ~HealthCare~ ~
33 II, 9. 1. 1| Perucci C. Cesarean (1992): section rates in Italy by hospital
34 II, 9. 1. 1| differences in rates of cesarean section. N Engl J Med 1989;321(4):
35 II, 9. 1. 2| registers, and the focus of this section. Many registers also include
36 II, 9. 1. 2| References cited in the section on congenital anomalies
37 II, 9. 1. 2| anomalies as presented in section 9.1.2.3. Comparisons of
38 II, 9. 2. 1| constitute a major part of the section of the community for which
39 II, 9. 2. 2| still focused on the adult section of the population – the
40 II, 9. 2. 3| indicated earlier in this section, injury is the greatest
41 II, 9. 2. 4| interactive data) (see also Section 10.2).~ ~Cannabis use. Cannabis
42 II, 9. 2. 4| interactive data) (see also Section 10.2).~ ~Sexual health and
43 II, 9. 3. 1| De Smedt, 2004).~ ~This section is also based on the International
44 II, 9. 3. 2| pain relief and Caesarean section).~ ~Morbidity~ ~Previous
45 II, 9. 3. 2| tubal ligation or caesarean section) or embolisation (3) blood
46 II, 9. 3. 2| higher rates of caesarean section for all countries in Europe.
47 II, 9. 3. 2| parity and previous caesarean section, and also by health system
48 II, 9. 3. 2| Perucci C. Cesarean (1992): section rates in Italy by hospital
49 II, 9. 3. 2| differences in rates of cesarean section. N Engl J Med 1989;321(4):
50 II, 9. 5. 2| and Accidents).~See also section 9.2 for additional data
51 III, 10. 2. 1| reported in the previous section. Plaque-induced chronic
52 III, 10. 2. 1| physical activity are quoted in section ”5.13. Obesity, overweight
53 III, 10. 2. 1| with in this Report (see section 5.2, 5.3 and 5.4), whereas
54 III, 10. 2. 5| determinants of health. The present section is built on scientific papers
55 III, 10. 2. 5| and quoted in the relevant section.~ ~The European Early Promotion
56 III, 10. 3. 2| organic pollutants. This section will address some emerging
57 III, 10. 3. 2| discussed in the following section in context with human biomonitoring.~ ~
58 III, 10. 4. 2| hazardous agents (see also Section 4.14.2).~ ~Apart from Regulation
59 III, 10. 4. 2| general information. A special section is devoted to the bovine
60 III, 10. 4. 2| Breast milk~ ~The Section on “Biomonitoring” in Chapter
61 III, 10. 5. 1| area.~ ~In the following section, the human settlement as
62 III, 10. 5. 2| accident injuries (see also Section 8.3.1.)~Different than for
63 III, 10. 6. 2| main data sources for this Section are :~· an independent comprehensive
64 III, 10. 6. 2| listed in the References Section.~ ~ ~ ~
65 IV, 11. 1. 1| discussion begins with a section on health systems performance
66 IV, 11. 1. 3| care. The remainder of this section identifies some of the key
67 IV, 11. 1. 4| Mossialos and Thomson 2003) (see Section 11.6 on Financing health
68 IV, 11. 1. 4| and Bakker 2002). See also Section 11.4.2 Public Health Services).~ ~
69 IV, 11. 1. 6| heavy state regulation (see Section 11.6 Financing Health Care).
70 IV, 11. 2 | provision~ ~The previous section addressed three key aspects
71 IV, 11. 2 | care, and efficiency. This section focuses on the delivery
72 IV, 11. 3 | discussed in the previous section, here we will see the issues
73 IV, 11. 6 | Financing healthcare~ ~This section reviews the ways in which
74 IV, 11. 6. 2| and quality of care. This section introduces the key trends
75 IV, 11. 6. 2| through tax allocations (see section on Social Health Insurance
76 IV, 11. 6. 2| and Mossialos, 2008) (see Section 11.8.3 on Progressivity).~ ~
77 IV, 11. 6. 3| resources are collected. This section considers how the funding
78 IV, 11. 6. 4| Robinson et al, 2005). See section 11.3.4. Technical efficiency
79 IV, 12. 2 | Policies” principle (see Section 12.7.), and is likely to
80 IV, 12. 2 | health determinant includes a section describing the current status
81 IV, 13. 7. 1| clusters as described in Section 4 of the Report on “Innovation
82 IV, 13. 8 | interests of a particular section of society;~They are autonomous
